UroCor Receives First Orders for Pacis BCG for Bladder Cancer Therapy.

Business Editors/Medical Writers

OKLAHOMA CITY--(BUSINESS WIRE)--June 20, 2000

UroCor, Inc., (Nasdaq: UCOR), announced today it has taken the first orders for PACIS(TM)BCG for the treatment of carcinoma in situ (CIS) in the urinary bladder. The drug is manufactured by BioChem Pharma and licensed for marketing in the U.S. by UroCor.

PACIS(R) contains live, attenuated mycobacteria. Because of the potential risk of transmission, it should be prepared, handled and disposed of as a biohazardous material.

Already approved for use in several other countries, including Canada, the drug features the original Bacillus Calmette-Guerin (BCG), substrain Montreal, for treating carcinoma-in-situ of the urinary bladder. The recommended course of treatment is a single dose, once per week, for six weeks, usually administered in the physician's office.

"We are excited about the initial demand for PACIS for two reasons," noted Michael W. George, President and CEO of UroCor. "First, this therapeutic will provide another therapy for urologists who treat patients with carcinoma-in-situ of the urinary bladder. Second, the marketing of PACIS advances UroCor's strategy to become a leading urological therapeutics company by leveraging our core skills and market channel in diagnostics, where we have established relationships with office-based urologists. Even though PACIS is not the first BCG therapeutic on the market," George said, "it is the only one with the original strain. With the launch of PACIS, we now have two therapeutic offerings including ProstaSeed, which are radiation implant seeds for the treatment of prostate cancer."

The Armand Frappier strain of BCG has more than 25 years of clinical experience worldwide.

According to the American Cancer Society, bladder cancer is the sixth most common cancer in the U.S., and the organization estimates there will be about 53,200 new cases reported this year and about 12,200 people will die of bladder cancer this year. In clinical studies of 292 patients, PACIS was well-tolerated, with the most common and serious adverse reactions being dysuria/cystitis (9%), increased urgency and frequency of urination (7%), and hematuria (6%)."

From a competitive standpoint, UroCor is the only U.S. marketer of BCG with a sales force that markets diagnostics and therapeutics to all office-based urologists. George said the company had trained a force of more than 50 sales representatives to call on office-based urologists, including those who are not already customers of UroCor's diagnostic lab services. Over 2,600 specialists currently utilize the company's urological specialty tests. Overall, there are approximately 7,800 office-based urologists.

BioChem Pharma Inc., headquartered in Laval, Quebec, Canada, is an international biopharmaceutical company dedicated to the research, development and commercialization of innovative products for the prevention and treatment of human disease, with a focus in the anti-infective and anticancer areas.

About UroCor

UroCor markets a comprehensive range of integrated products and services to assist in detecting, diagnosing, treating and managing prostate cancer, bladder cancer, kidney stones and other complex urologic disorders directly to urologists and managed care organizations. The Company's primary focus is helping urologists improve patient care and outcomes while reducing the total cost of managing these diseases. The Company presently serves many of the office-based urologists in the United States, many of them over its Internet-based wide area network.

Statements in this news release that are not strictly historical, including statements as to plans, objectives and future financial performance, are "forward-looking" statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Although UroCor believes that the expectations reflected in such forward-looking statements are reasonable; it can give no assurance that the expectations will prove to be correct. Factors that could cause actual results to differ materially from UroCor's expectations include, among others, competition within the healthcare and medical services industries; the effects of government regulation and reimbursement policies on the healthcare market and the Company, including the possibility of being deemed not to be in compliance with federal or state regulatory requirements; the Company's access to and the market's acceptance of new diagnostic and therapeutic products; the Company's ability to market and distribute diagnostic and therapeutic products profitably; the Company's ability to maintain or expand contractual relationships with managed care organizations; Company's ability to acquire or develop and implement appropriate management information systems; as well as the risks, uncertainties and other factors described from time to time in the Company's periodic filings with the Securities and Exchange Commission.

Visit the UroCor website @ www.urocor.com